Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
EASD 25: EMPIRE-PREVENT: Metabolic Effects of Empagliflozin in Patients at Risk of Heart Failure
Author(s): Camilla Andersen Added: 8 months ago
EASD Congress 2025 - Dr Camilla Andersen (The University of Western Australia, Perth, AU) joins us to discuss findings from the EMPIRE-PREVENT: Metabolic study, investigating the metabolic effects of empagliflozin in elderly and obese patients at high risk of developing heart failure (HF).This randomized controlled trial evaluated 165 patients aged 60–84 years with obesity (BMI >28kg/m²) and… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Research Area(s) / Expertise: Job title: Advocate for Obesity; EPCO Secretary
Susie Birney lives with a food disorder called ARFID; she understands that there is not only one cause for obesity and not one treatment which will always work. Type 2 Diabetes and other co-morbidities have been health barriers for her since her 30’s. Since 2016, Susie has been a patient representative with the ASOI and an Irish representative with ECPO. This led to the start of creating a… View more
ECO 25: The RESET Trial
Author(s): Donna H Ryan Added: 1 year ago
ECO 2025 - Findings from the RESET trial show early weight loss with an oral, shape-shifting, superabsorbent, hydrogel capsule was superior to placebo and predicted long-term success in patients with overweight and obesity.Dr Donna Ryan (Pennington Biomedical, Baton Rouge, US) joins us to discuss findings from RESET (NCT04222322; Epitomee Medical). The prospective, randomised, double-blind,… View more

Cardiovascular Kidney Metabolic
Research Area(s) / Expertise: Job title: Chief Medical Officer
Dr Lydia Alexander is Chief Medical Officer at Enara Health in San Mateo, California. Dr Alexander earned her medical degree at the UC Davis School of Medicine,Sacramento, California; then completed an internal medicine residency at Kaiser Permanente, followed by a chief residency at Kaiser Hospital, both in California. She is trained as a culinary medicine specialist from Tulane University, New… View more
ECO 24: Increasing GLP1-RA Efficacy by Targeting Non-coding RNA
Author(s): Riccardo Panella Added: 2 years ago
ECO 2024 — Dr Riccardo Panella (Aalborg University, DK) joins us to discuss a ncRNA-based approach in treating obesity. This new combinatory treatment (Resalis) aims to increase GLP1-RA efficacy by targeting non-coding RNA.Questions1. What is the background of this combinatory approach?2. What data did you present at ERA 24?3. What are the challenges and opportunities in approaching combinatory… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
HFA 24 Late-Breaker Discussion: Insights from the STEP-HFpEF
Author(s): Harriette Van Spall , Mikhail Kosiborod Added: 2 years ago
HFA 2024 — Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) sat down with Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss insights from the STEP-HFpEF programme.STEP HFpEF aimed to test the hypothesis that treatment with semaglutide can improve symptoms in patients with HFpEF and obesity. This discussion centers around the background of the… View more

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Research Area(s) / Expertise: Job title: Medical Director and President
Dr Harold Bays is Medical Director and President of the Louisville Metabolic and Atherosclerosis Research Center, US. He has served as a Principal Investigator for over 600 clinical trials of metabolic therapeutic interventions.Dr Bays is Board Certified in Internal Medicine and Endocrinology and Metabolism, Diplomate of the American Board of Obesity Medicine, and a Diplomate of the American… View more
Eloralintide Shows Significant Weight Loss in Phase 2 Trial
Added: 7 months ago Source:  Radcliffe CVRM
A novel, selective amylin receptor agonist, eloralintide, has demonstrated significant, dose-dependent weight loss in adults with obesity or overweight, according to the results of a 48-week phase 2 trial (NCT06230523).¹ Amylin-based therapies are an emerging class of promising medications for weight management.²This multicentre, double-blind, randomised, placebo-controlled trial was conducted… View more

Cardiovascular Kidney Metabolic
Effects of GLP-1 Receptor Agonists in Heart Failure Patients
Author(s): Anastasia Shchendrygina , Amina Rakisheva , Ilya Giverts , et al Added: 1 year ago

Heart Failure
HFpEF-ABA Score Outperforms NT-proBNP in Trial Enrichment
Added: 6 months ago Source:  Radcliffe Cardiology
A new post hoc analysis of the SUMMIT trial suggests the HFpEF-ABA score is a more effective and inclusive enrichment tool than natriuretic peptide (NP) levels for clinical trials in patients with obesity-related heart failure with preserved ejection fraction (HFpEF).¹ The findings indicate the score, which is based on age, body mass index (BMI), and history of atrial fibrillation (AF), can… View more

Imaging & Diagnostics

Cardiovascular Kidney Metabolic